Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 918385204 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Millennium Management LLC
13G/A
Amendment 3
|
8.7% |
10/8/2026
Event 9/30/2026
|
|
| Integrated Core Strategies (US) LLC | 7.9% | ||
| Millennium Management LLC | 8.7% | ||
| Millennium Group Management LLC | 8.7% | ||
| Israel A. Englander | 8.7% | ||
|
Millennium Management LLC
13G/A
Amendment 2
|
6.9% |
7/29/2026
Event 6/30/2026
|
|
| Integrated Core Strategies (US) LLC | 6.3% | ||
| Millennium Management LLC | 6.9% | ||
| Millennium Group Management LLC | 6.9% | ||
| Israel A. Englander | 6.9% | ||
|
Millennium Management LLC
13G/A
Amendment 1
|
5.7% |
4/16/2026
Event 4/13/2026
|
|
| Integrated Core Strategies (US) LLC | 5.0% | ||
| Millennium Management LLC | 5.7% | ||
| Millennium Group Management LLC | 5.7% | ||
| Israel A. Englander | 5.7% | ||
|
Millennium Management LLC
13G
|
5.0% |
3/27/2026
Event 3/24/2026
|
|
| Millennium Management LLC | 5.0% | ||
| Millennium Group Management LLC | 5.0% | ||
| Israel A. Englander | 5.0% | ||
|
Samsara BioCapital, L.P.
13D/A
Amendment 3
|
9.9% |
12/9/2025
Event 12/8/2025
|
|
| Samsara BioCapital, L.P. | 6.2% | ||
| Samsara BioCapital GP, LLC | 6.2% | ||
| Samsara Opportunity Fund, L.P. | 3.8% | ||
| Samsara Opportunity Fund GP, LLC | 3.8% | ||
| Srinivas Akkaraju | 9.9% | ||
|
Invus Global Management, LLC
13G/A
Amendment 1
|
9.4% |
11/12/2025
Event 9/30/2025
|
|
| Invus Public Equities, L.P. | 8.4% | ||
| Invus Public Equities Advisors, LLC | 8.4% | ||
| Invus Global Management, LLC | 8.4% | ||
| Siren, L.L.C. | 8.4% | ||
| Avicenna Life Sci Master Fund LP | 1.2% | ||
| Avicenna Life Sci Master GP LLC | 1.2% | ||
| Ulys, L.L.C. | 1.2% | ||
| Raymond Debbane | 9.4% | ||
|
Samsara BioCapital, L.P.
13D/A
Amendment 2
|
9.9% |
9/25/2025
Event 9/22/2025
|
|
| Samsara BioCapital, L.P. | 6.5% | ||
| Samsara BioCapital GP, LLC | 6.5% | ||
| Samsara Opportunity Fund, L.P. | 3.5% | ||
| Samsara Opportunity Fund GP, LLC | 3.5% | ||
| Srinivas Akkaraju | 9.9% | ||
|
Invus Global Management, LLC
13G
|
10.0% |
9/8/2025
Event 8/29/2025
|
|
| Invus Public Equities, L.P. | 8.8% | ||
| Invus Public Equities Advisors, LLC | 8.8% | ||
| Invus Global Management, LLC | 8.8% | ||
| Siren, L.L.C. | 8.8% | ||
| Avicenna Life Sci Master Fund LP | 1.3% | ||
| Avicenna Life Sci Master GP LLC | 1.3% | ||
| Ulys, L.L.C. | 1.3% | ||
| Raymond Debbane | 10.0% | ||
|
Trails Edge Capital Partners, LP
13G
|
9.9% |
9/8/2025
Event 8/29/2025
|
|
| Trails Edge Capital Partners, LP | 9.9% | ||
| Trails Edge Biotechnology Master Fund, LP | 9.9% | ||
| Ortav Yehudai | 9.9% | ||
|
Samsara BioCapital, L.P.
13D/A
Amendment 1
|
9.9% |
9/3/2025
Event 8/29/2025
|
|
| Samsara BioCapital, L.P. | 9.9% | ||
| Samsara BioCapital GP, LLC | 9.9% | ||
| Srinivas Akkaraju | 9.9% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 328 | $10.1 k |
| 2026 Q2 | 45 | 1.61 M | $60.5 M |
| 2026 Q1 | 35 | 1.49 M | $59.0 M |
| 2025 Q4 | 27 | 1.28 M | $51.3 M |
| 2025 Q3 | 23 | 988 k | $23.1 M |
| 2025 Q2 | 22 | 587 k | $8.74 M |
| 2025 Q1 | 22 | 572 k | $9.90 M |
| 2024 Q4 | 18 | 551 k | $7.57 M |
| 2024 Q3 | 21 | 542 k | $7.34 M |
| 2024 Q2 | 22 | 349 k | $6.16 M |
| 2024 Q1 | 23 | 335 k | $7.89 M |
| 2023 Q4 | 17 | 69.5 k | $798 k |
| 2023 Q3 | 1 | 600 | $287.00 |